ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio, Inc. (IBRX) announced that the FDA expanded ANKTIVA’s approved use in combination with BCG to adult patients with BCG-unresponsive non-muscle invasive bladder cancer, including patients with papillary-only tumors. The earlier approval covered patients with carcinoma in situ (CIS), with or without papillary tumors.
In Cohort A of QUILT-3.032, 62% of 77 patients achieved a complete response (95% CI: 51, 73); among responders, 58% maintained a response for at least 12 months and 40% for at least 24 months. Prescribing information warns that delaying cystectomy can lead to muscle-invasive or metastatic bladder cancer, which can be lethal, and says to reconsider cystectomy if high-grade disease is present after a second induction course of ANKTIVA with BCG.
ImmunityBio, Inc. (IBRX) director Barry J. Simon reported selling 25,000 shares on October 5, 2026, at a weighted average price of $10.7504 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted December 18, 2025. After the sale, Simon reported directly holding 2,777,788 shares.
ImmunityBio, Inc. director Cheryl Cohen exercised options for 55,979 shares at a $2.98 exercise price and acquired 55,979 common shares on October 2, 2026. She also sold 81,056 common shares at $10.50 per share that day. The sale was made pursuant to a Rule 10b5-1 trading plan entered into on February 27, 2026. The option record lists June 14, 2032, as its expiration date.
ImmunityBio, Inc. (IBRX) reported a proposed sale by officer and director Barry J. Simon of 560,000 common shares, with an aggregate market value of $7,657,760.00 and an approximate sale date of October 5, 2026. The reported securities are listed with an open-market transaction dated December 31, 2013.
ImmunityBio, Inc. director Cheryl Cohen reported a proposed sale of 81,056 common shares, with an aggregate market value of $752,199.68 and an approximate sale date of October 2, 2026. The listed shares include 55,979 shares acquired through exercise of stock options on October 2, 2026, and 25,077 shares acquired as restricted stock units on June 6, 2019.
ImmunityBio, Inc. is reported to be majority-controlled by Patrick Soon-Shiong and affiliated entities. They beneficially own 745,518,285 shares of common stock, representing 64.8% of the class, based on the issuer’s share counts as of July 31, 2026.
Key reporting entities include Cambridge Equities, LP with 261,705,814 shares (24.7%), Nant Capital, LLC with 339,465,528 shares (29.6%), California Capital Equity, LLC with 106,511,412 shares (10.0%), and NantWorks, LLC with 98,535,253 shares (9.3%). Several entities and Dr. Soon-Shiong also hold rights to acquire additional shares within 60 days through stock options and a convertible promissory note, and the structure involves multiple wholly owned and majority-owned subsidiaries through which voting and dispositive power is shared.
ImmunityBio, Inc. reported record Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially, marking its eighth consecutive quarter of sequential growth since the commercial launch of ANKTIVA. First-half 2026 net product revenue reached $94.8 million, up 121% versus the first half of 2025. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $357.4 million.
GAAP net loss attributable to common stockholders was $230.4 million in Q2 2026 and $863.2 million for the first half, mainly driven by non-cash changes in the fair value of warrant and derivative liabilities and a related-party convertible note, as well as higher R&D, SG&A and revenue-interest-related interest expense. Adjusted net loss improved to $81.0 million in Q2 2026 and $167.3 million for the first half. Operationally, ImmunityBio reported broader ANKTIVA access, including marketing authorization in the United Arab Emirates, FDA acceptance of an sBLA with a PDUFA target action date of January 6, 2027, and an exclusive U.S. supply agreement for Tokyo-172 BCG.
ImmunityBio, Inc. reports that the Emirates Drug Establishment in the United Arab Emirates has granted Marketing Authorization for ANKTIVA across two indications: BCG-unresponsive non-muscle invasive bladder cancer (including carcinoma in situ and papillary-only disease) and metastatic non-small cell lung cancer after progression on checkpoint inhibitor–based therapy.
The bladder cancer authorization, described as the first worldwide to span the full spectrum of BCG-unresponsive disease, is supported by QUILT-3.032, where ANKTIVA plus BCG produced a 71% complete response rate in the CIS cohort (N=100) and a 12-month disease-free survival rate of 58.2% in papillary-only patients (N=80); Grade 3 treatment-related adverse events occurred in 1% of patients, with no Grade 4 or 5 events reported. The lung cancer indication is backed by QUILT-3.055, showing median overall survival of 14.6 months in checkpoint-refractory advanced NSCLC (N=79) and 16.2 months in patients achieving higher absolute lymphocyte counts. With this decision, ANKTIVA is now authorized in 34 countries, including the UAE, United States, United Kingdom, Saudi Arabia and the European Union.
ImmunityBio, Inc. director Cheryl Cohen reported an exercise-and-sale transaction involving the company’s common stock. On 2026-07-02, she sold 131,210 shares in an open‑market transaction at a weighted average price of $9.5034 per share, under a pre‑arranged Rule 10b5-1 trading plan.
On the same date, Cohen exercised stock options to acquire 55,979 common shares at an exercise price of $2.98 per share, reducing her option position while increasing her direct shareholdings before the sale. Following these transactions, she directly holds 125,386 common shares and 111,958 stock options.